Relation between activated clotting time during angioplasty and abrupt closure

Circulation

Volumn 93, Issue 4, 1996, Pages 667-671

  Narins, Craig R ^a   Hillegass Jr , William B ^a   Nelson, Charlotte L ^a   Tcheng, James E ^a   Harrington, Robert A ^a   Phillips, Harry R ^a   Stack, Richard S ^a   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angioplasty; anticoagulants; complications; heparin

Indexed keywords

HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0030042639     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.4.667     Document Type: Article

References (24)

1. Detre KM, Holmes DR, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM, Myler RK. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990;82: 739-750.
2. de Feyter PJ, van den Brand M, Jaarman G, van Domburg K, Serruys PW, Suryapranata H. Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation. 1991;83:927-936.
3. Scott NA, Weintraub WS, Carlin SF, Tao X, Douglas JS, Lembo NJ, King SB. Recent changes in the management and outcome of acute closure after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1993;71:1159-1163.
4. de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J. 1994;127:643-651.
5. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic, and therapeutic profile. J Am Coll Cardiol. 1992;19: 926-935.
6. Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam JYT, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation. 1988;78:654-660.
7. Tenaglia AN, Tcheng JE, Phillips HR. Coronary angioplasty: femoral approach. In: Roubin GS, Califf RM, O'Neill W, Phillips HR, Stack RS, eds. Interventional Cardiovascular Medicine: Principles and Practice. New York, NY: Churchill Livingstone; 1994: 439-450.
8. TIMI Study Group. The thrombolysis in myocardial infarction trial. N Engl J Med. 1985;313:342-347.
9. Tenaglia AN, Fortin DF, Califf RM, Frid DJ, Nelson CL, Gardner LH, Miller M, Navetta FI, Smith JE, Tcheng JE, Stack RS. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J Am Coll Cardiol. 1994;24:1004-1011.
10. Favereau X, Corcos T, Zimarino M, Tamburino C, Guérin Y, Toussaint M, Souffrant G. Is ABC classification for PTCA obsolete? Circulation. 1993;88(suppl I):I-207. Abstract.
11. de Feyter PJ, Suryapranata J, Serruys P, Beatt KJ, van Domburg R, van den Brand M, Tijssen JJ, Azar AJ, Hugenholtz PG. Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification of risk factors for unfavorable early and late outcome. J Am Coll Cardiol. 1988;12:324-333.
12. Wolfe MW, Leya F, Bonan R, Ferguson JJ, Roubin GS, Schwaiger MJ, Cleman M, Cabin H, McAllister A, Adelman B, Bittl JA. Predictors of outcome after balloon angioplasty: a prospective multicenter study. Circulation. 1993;88(suppl I):I-300. Abstract.
13. Haltersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436-440.
14. Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J. 1990;63:18-21.
15. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn. 1989;18:206-209.
16. Cox DR. The regression analysis of binary sequences. J R Stat Soc. 1958;20:215-242.
17. Harrell FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198-1202.
18. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318: 1714-1719.
19. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
20. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn. 1993;28:279-282.
21. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated clotting time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1061-1065.
22. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87:1622-1629.
23. Westerhauser DR, Bailey WL, Hartzler GO, McConahy DR, Johnson WL, Giorgi LL, Shimshak TM, Ligon RW, Rutherford BD. Determinants of procedural outcome with PTCA in the 1990s. Circulation. 1993;88(suppl I):I-217. Abstract.
24. Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994; 23:907-910.